4D Molecular Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
4D Molecular Therapeutics, Inc. (FDMT) reported Capital Expenditures Incurred but Not yet Paid of $49.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $49.00K.
- 4D Molecular Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- 4D Molecular Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was -$140.00K, a 179.10% decline year-over-year.
- 4D Molecular Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $140.00K.
- 4D Molecular Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $509.00K, a 117.52% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $234.00K, a 75.03% decline from fiscal 2022.
- 4D Molecular Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $937.00K, a 57.39% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $49.00K 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-03-18 | |||
| 2025-06-30 | -$140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | -$185.00K derived: sum of 3 quarters · filed 2026-08-13 | $332.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $140.00K 10-Q · filed 2026-05-07 | -$45.00K derived: sum of 2 quarters · filed 2026-05-07 | $472.00K derived: sum of 3 quarters · filed 2026-05-07 | $649.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $332.00K derived: sum of 2 quarters · filed 2026-03-18 | $509.00K derived: sum of 3 quarters · filed 2026-03-18 | $509.00K 10-K · filed 2026-03-18 |
| 2024-09-30 | $517.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $694.00K derived: sum of 2 quarters · filed 2025-11-10 | $694.00K 10-Q · filed 2025-11-10 | $583.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $177.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $177.00K 10-Q · filed 2025-08-11 | $66.00K derived: sum of 3 quarters · filed 2025-08-11 | $99.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | -$111.00K derived: sum of 2 quarters · filed 2025-02-28 | -$78.00K derived: sum of 3 quarters · filed 2025-02-28 | -$123.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$78.00K derived: sum of 2 quarters · filed 2025-02-28 | -$123.00K derived: sum of 3 quarters · filed 2025-02-28 | $234.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$12.00K derived: sum of 2 quarters · filed 2024-11-13 | $345.00K 10-Q · filed 2024-11-13 | $985.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $312.00K 10-Q · filed 2024-08-08 | $952.00K derived: sum of 3 quarters · filed 2024-08-08 | -$49.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $357.00K 10-Q · filed 2024-05-09 | $997.00K derived: sum of 2 quarters · filed 2024-05-09 | -$4.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.04M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $640.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$361.00K derived: sum of 2 quarters · filed 2024-02-29 | $680.00K derived: sum of 3 quarters · filed 2024-02-29 | $937.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $40.00K derived: sum of 2 quarters · filed 2023-11-09 | $297.00K 10-Q · filed 2023-11-09 | $1.19M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.30M 10-Q · filed 2023-08-09 | $2.19M derived: sum of 3 quarters · filed 2023-08-09 | $3.15M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $257.00K 10-Q · filed 2023-05-11 | $1.15M derived: sum of 2 quarters · filed 2023-05-11 | $2.11M derived: sum of 3 quarters · filed 2023-05-11 | $2.31M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $896.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.85M derived: sum of 2 quarters · filed 2023-03-15 | $2.05M derived: sum of 3 quarters · filed 2023-03-15 | $2.20M 10-K · filed 2023-03-15 |
| 2021-09-30 | $956.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.16M derived: sum of 2 quarters · filed 2022-11-08 | $1.30M 10-Q · filed 2022-11-08 | $1.26M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $347.00K 10-Q · filed 2022-08-11 | $301.00K derived: sum of 3 quarters · filed 2022-08-11 | $509.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $145.00K 10-Q · filed 2022-05-12 | $99.00K derived: sum of 2 quarters · filed 2022-05-12 | $307.00K derived: sum of 3 quarters · filed 2022-05-12 | $597.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $162.00K derived: sum of 2 quarters · filed 2022-03-28 | $452.00K derived: sum of 3 quarters · filed 2022-03-28 | $466.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $498.00K derived: sum of 2 quarters · filed 2021-11-10 | $512.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $290.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $304.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $14.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $385.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |